Behçet

Behçet

  
Hatemi G et al. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015 Apr 16;372(16):1510-8.Lire le résumé
Mohammad AJ et al. Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience. J Rheumatol. 2015 Oct;42(10):1906-13Lire le résumé
Berteau F, Rouviere B, Delluc A, Nau A, Le Berre R, Sarrabay G, et al. Autosomic dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. Autoimmun Rev. août 2018;17(8):809 15

Lire le résumé
De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of
apremilast for Behçet’s syndrome: a real-life single-centre Italian experience. Rheumatology [Internet]. 5 juill 2019 [cité 22 juill 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-
article/doi/10.1093/rheumatology/kez267/5529163
Lire le résumé
Hatemi G, Mahr A, Ishigatsubo Y, Song Y-W, Takeno M, Kim D, et al. Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome. N Engl J Med. 14 nov 2019;381(20):1918 28
Lire le résumé
Thomas T, Chandan JS, Subramanian A, Gokhale K, et al. Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN). 2020 Feb 10. Lire le résumé
Fagni F, Bettiol A, Talarico R, Lopalco G, Silvestri E, Urban ML, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study. Ann Rheum Dis. 7 mai 2020;annrheumdis-2020-217108.
Lire le résumé
Manthiram K, Preite S, Dedeoglu F, Demir S, Ozen S, Edwards KM, et al. Common genetic susceptibility loci link PFAPA syndrome, Behçet’s disease, and recurrent aphthous stomatitis. Proc Natl Acad Sci. 9 juin 2020;202002051
Lire le résumé